ClinicalTrials.gg
RecruitingNCT07282353Updated Nov 12, 2026

A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

A Phase 3 interventional study of 2mg CS0159 and Placebo in Primary Biliary Cholangitis, sponsored by Cascade Pharmaceuticals, Inc. Recruiting at 41 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Cascade Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 12, 2026Site recruiting status changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 52 studies in Liver Cirrhosis, Biliary with a site in China — 16 open to participants now, 20 under way, 11 of them phase 3. Liver Cirrhosis, Biliary · China.

Planned enrollment
15th of 43
135 · median 104
Started
2025
with 4 others
Phase 3
14 of 52
7 open now
Primary completion
2027-12
later than 8 of 19 live
Registered
48th of 52
by date
Lead sponsor
5 of 52
Cascade Pharmaceuticals, Inc

Among the 52 studies in Liver Cirrhosis, Biliary with a site in China, this one is the 15th largest by planned enrollment of the 43 interventional ones that give a count, is one of 5 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 8 of the 19 other live ones, and was the 48th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

16 of the 52 studies in Liver Cirrhosis, Biliary with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Liver Cirrhosis, Biliary with a site in China, or all of them as a file.
02

Study summary

A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients with Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (UDCA).

Read the detailed description

This is an multicenter, randomized, double-blind, placebo-controlled, parallel-group study that evaluates the efficacy and safety of CS0159 in patients with PBC who have inadequate response or intolerance to ursodeoxycholic acid (UDCA). Approximately 135 participants will be randomized in a 2:1 ratio to receive CS0159 (4 mg) or placebo, once daily, for a maximum of 52 weeks. When applicable, study participants should continue their pre-study dose of UDCA.

03

Conditions studied

  • Primary Biliary Cholangitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written (signed and dated) and any authorizations required by local law;
  2. When signing ICF age ≥18 years ≤75 years, male or female;
  3. Meets the diagnostic criteria of PBC, based on any two of the following criteria:

    1. History of ALP above 1.0× for at least 6 months
    2. Positive antimitochondrial antibody (AMA) titer (>1:40 on immunofluorescence or M2 positive by ELISA) or positive PBC- specific antinuclear antibody (ANA) (either SP100 or GP210 positive)
    3. Documented liver results consistent with PBC;
  4. UDCA≥6 months before randomization and a stable dose ≥3 months after the efficacy was poor [meeting inclusion criteria (5)a], or UDCA was not tolerated, and stop taking UDCA (no UDCA use for ≥3 months before randomization);
  5. Laboratory parameters measured at screening period meet the following criteria:

    1. ALP ≥1.67× ULN
    2. ≤5× ULN
    3. AST ≤5× ULN
    4. TB \<2× ULN
    5. Estimated (eGFR) > 60mL/min/1.73m2 (calculated by CKD-EPI equation)
    6. count ≥ 1.0× LLN (No thrombocytopenia-related treatment within the past two weeks)
    7. Albumin> 35g/L
    8. White blood cells count (WBC) >3×109/L
    9. (ANC) >1.5×109/L
    10. (HbA1c) ≤9.0%;
  6. ≤ 1.0× ULN. For participants on anticoagulation therapy, INR must be maintained in the range required for prophylaxis for their specific disease;
  7. Females of must use at least 1 barrier and a second effective birth control method during the study and for at least 90 days after the last dose. Male participants who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose.

    -

Exclusion criteria

Exclusion Criteria:

  1. Previous exposure to CS0159;
  2. History of allergy to the CS0159 or its or drugs of similar chemical classes;
  3. Advanced PBC as defined by the Rotterdam criteria (albumin\<1.0×LLN AND TB >1.0× );
  4. Patients who have had complications of hepatic cirrhosis with clinically significant portal hypertension (CSPH), including the following:

    1. History of liver transplantation, current placement on a liver transplant list, current MELD -Na score ≥ 12;
    2. History of confirmed esophagogastric variceal bleeding;
    3. Clinically significant ascites requiring intervention, such as sodium restriction, diuretic therapy, or therapeutic paracentesis;
    4. Any secondary complications resulting from clinically significant ascites, such as spontaneous bacterial peritonitis, hepatorenal syndrome, or hepatic hydrothorax;
    5. Hepatic encephalopathy requiring drug therapy;
    6. Portopulmonary hypertension and/or hepatopulmonary syndrome;
    7. Hepatocellular carcinoma;
  5. Other concomitant liver disease including:

    1. hepatitis (AIH) (simplified AIH diagnostic score >6), PBC-AIH overlap syndrome, or overlap with other autoimmune liver diseases
    2. Positive or positive (tested for in case of known cured HCV infection or positive HCV Ab at screening)
    3. Primary sclerosing cholangitis (PSC)
    4. History or clinical evidence of Alcoholic liver disease (ALD)
    5. confirmed Non-alcoholic steatohepatitis (NASH)
    6. Gilbert's Syndrome
    7. History or evidence of alpha-1 antitrypsin deficiency
    8. Liver stiffness measured by transient elastography (TE) > 16.9 Kpa;
  6. Patient has a positive test for at screening, or active syphilis [defined as positive Treponema pallidum antibody (TP Ab) and a rapid plasma reagin (RPR) card test titer ≥1:8; for low titers (e.g., 1:1 or 1:2), clinical judgment is required to determine if it is active syphilis];
  7. Administration of the following medications are prohibited as specified below:

    1. Use of medications, food, and drinks (e.g., grapefruit juice) that are strong or moderate inhibitors or inducers within 14 days before randomization;
    2. Use of P-glycoprotein (P-gp) substrate drugs within 14 days before randomization;
    3. 2 months prior to randomization: fibrates, glitazones, seladelpar and elafibranor.
    4. 3 months prior to randomization: obeticholic acid (OCA), azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, systemic and budesonide (˃2 weeks); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid isoniazid, or nitrofurantoin).
    5. Patients with systemic treatment for pruritus (e.g., with bile acid sequestrants [BAS]) within 3 months prior to randomization.
    6. 12 months prior to randomization: antibodies or immunotherapy directed against ILs or other cytokines or chemokines;
  8. Medical conditions that may cause non-hepatic increases in ALP (e.g., paget's disease);
  9. Patients with severe arrhythmia, or a interval corrected by Fridericia's formula ≥450 ms (males) or ≥470 ms (females) at screening [Fridericia's formula: QTcF=QT/(RR\^0.33)];
  10. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the large intestine, eg, inflammatory bowel disease, prior or planned (during the study period) bariatric surgery (such as gastroplasty, roux-en-Y gastric bypass);
  11. History of (except for those with a disease-free survival of ≥5 years) or currently under evaluation for malignancy. Except for cases with long-term stable disease and assessed by the investigator as having no significant impact on the trial-such as cured squamous or non-invasive basal cell skin carcinoma, cervical carcinoma in situ, mild to moderate cervical dysplasia, or incidental prostate cancer stage T1a.
  12. Drug abuse or heavy alcohol use from 12 months prior to randomization throughout the entire clinical study period. Heavy alcohol use is defined as an average weekly alcohol consumption of more than approximately 7 standard drinks for females and more than approximately 14 standard drinks for males. One standard drink is defined as any beverage containing 14g of pure alcohol, such as 12 oz/360 mL of beer (5% alcohol), 8 oz/240 mL of malt liquor (7% alcohol), 5 oz/150 mL of wine (12% alcohol), or 1.5 oz/45 mL of distilled spirits (40% alcohol);
  13. Poor blood pressure control is indicated after treatment by a systolic pressure greater than 160 mmHg or diastolic pressure greater than 100 mmHg during screening;
  14. Pregnancy, planned pregnancy, lactation;
  15. Treatment with any other therapy or device within 30 days or within 5 half-lives, whichever is longer, prior to screening;
  16. Mental instability or incompetence that may compromise the validity of or ability to adhere to study requirements;
  17. Any other condition(s) that would compromise the safety of the patient or compromise the quality of the clinical study, as judged by the investigator.

    -

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    4 mg CS0159

    Take 4mg of CS0159 QD for 52 weeks.

    Drug: 2mg CS0159

  • Placebo comparator
    placebo

    Take placebo QD for 52 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of patients who achieve the composite response criteria at Week 52

    1. ALP \< 1.67×ULN 2. and ALP decrease of ≥15% 3. and TB ≤1.0× ULN

    Time frame: Baseline to week 52 .

Secondary outcomes

  1. Response to treatment based on γ-glutamyl transpeptidase (GGT) normalization in patients with baseline GGT>1.0× ULN at Week 26 and Week 52

    Time frame: Basline to week 26 and week 52 .

  2. Response to treatment based on alanine aminotransferase (ALT) normalization in patients with baseline ALT >1.0× ULN at Week 26 and Week 52

    Time frame: Basline to week 26 and week 52 .

  3. Proportion of patients with ALP< 1.67× ULN and TB ≤1.0× ULN and ALP decrease of ≥15% from baseline at Week 26

    Time frame: Baseline to week 26 .

  4. Response to treatment based on AST normalization in patients with baseline AST>1.0× ULN at Week 26 and Week 52

    Time frame: Baseline to week 26 and week 52 .

  5. Proportion of patients with ALP≤ 3× ULN and AST ≤ 2 × ULN and TB≤ 1.0×ULN at Week 52

    Time frame: Baseline to week 52 .

  6. The first occurrence of clinical outcome events as defined

    Overall death Liver transplantation Model for End-Stage Liver Disease (MELD)-Na score \>14 for at least 2 consecutive visits Ascites requiring treatment Hospitalization for new onset or recurrence of any of the following: i. Variceal bleeding ii. Hepatic encephalopathy (as defined by a West Haven score ≥2) iii. Spontaneous bacterial peritonitis (confirmed by culture from diagnostic paracentesis).

    Time frame: up to 56 weeks

  7. Assessment of treatment-emergent AEs (TEAEs)

    Safety

    Time frame: up to 56 weeks

Other outcomes

  1. Absolute changes of liver stiffness measured by iLivTouch

    Time frame: week 26, week 52

07

Study locations

41 of 41 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 15, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 9, 2027
CompletionEst.
Jan 6, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • The Fourth People's Hospital of Qinghai Province · Xining, ChinaNot yet recruiting→Recruiting
  • Ningbo Medical Center Li Huili hospital · Ningbo, ChinaNot yet recruiting→Recruiting
Show 1 removed
  • Zhongnan Hospital of Wuhan University · Wuhan, China
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • The Fourth People's Hospital of Qinghai Province · Xining, ChinaNot yet recruiting→Recruiting
    • Ningbo Medical Center Li Huili hospital · Ningbo, ChinaNot yet recruiting→Recruiting
    Show 1 removed
    • Zhongnan Hospital of Wuhan University · Wuhan, China

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07282353
Lead sponsor
Cascade Pharmaceuticals, Inc
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Dec 1, 2025
Primary completion
Dec 9, 2027 (estimated)
Completion
Jan 6, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Ma Xiong, MD
Contact
maxiongmd@163.com
15900984550
Xiao Xiao, MD
Contact
xxiao_sh@163.com
15921514136
Ma Xiong, MD
principal investigator · Renji Hospital, School of Medicine, Shanghai Jiao Tong University.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linafexor

Start the discussion